E. Ohman J:or Asset Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$38.6M |
| 2 |
Stryker
SYK
|
+$37.7M |
| 3 |
Capital One
COF
|
+$33.6M |
| 4 |
Dover
DOV
|
+$31M |
| 5 |
RadNet
RDNT
|
+$23.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cboe Global Markets
CBOE
|
+$56.7M |
| 2 |
Gilead Sciences
GILD
|
+$44.4M |
| 3 |
AT&T
T
|
+$34.8M |
| 4 |
Intuit
INTU
|
+$32.5M |
| 5 |
Boston Scientific
BSX
|
+$29.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 43.83% |
| 2 | Financials | 13.15% |
| 3 | Healthcare | 10.01% |
| 4 | Communication Services | 9.79% |
| 5 | Consumer Discretionary | 8.15% |
No holdings matched the selected filter criteria.
Similar funds
E. Ohman J:or Asset Management's Q2 2026 Portfolio in Review
As of Q2 2026, E. Ohman J:or Asset Management held 487 positions worth $4.3B, up 14% from $3.78B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
E. Ohman J:or Asset Management's Q2 2026 filing shows 10 new, 143 increased, 81 reduced and 22 closed positions. Its largest new stake was Denali Therapeutics: 160,000 shares worth $4.12M. The largest sale was Cboe Global Markets, an estimated $56.7M.
By sector, the portfolio is most concentrated in Technology at 44% of assets, up from 42% a quarter earlier, followed by Financials and Healthcare.
- E. Ohman J:or Asset Management's largest Q2 2026 buy was Denali Therapeutics: 160,000 shares worth $4.12M.
- E. Ohman J:or Asset Management added most to Eli Lilly in Q2 2026, an estimated $38.6M increase.
- E. Ohman J:or Asset Management's biggest Q2 2026 reduction was Cboe Global Markets, cutting an estimated $56.7M.
- E. Ohman J:or Asset Management fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $1.17M.
- E. Ohman J:or Asset Management's ten largest holdings make up 43% of its $4.3B portfolio in Q2 2026.
- E. Ohman J:or Asset Management opened 10 new positions and closed 22 in Q2 2026.
- E. Ohman J:or Asset Management's portfolio value rose 14% quarter-over-quarter to $4.3B.
Based on E. Ohman J:or Asset Management's 13F filing for Q2 2026, filed 10 Jul 2026.